Over-expression of CEACAM6 is documented in many human epithelial (e.g. colorectal, breast, pancreatic ductal adenocarcinoma (PDA))6,7 and hematologic malignancies (e.g. multiple myeloma and acute lymphoblastic leukemia)5. Here, CEACAM6 is linked to pancreatic ductal adenocarcinoma.